|
Gene: SEC22C |
Gene summary for SEC22C |
Gene summary. |
Gene information | Species | Human | Gene symbol | SEC22C | Gene ID | 9117 |
Gene name | SEC22 homolog C, vesicle trafficking protein | |
Gene Alias | SEC22L3 | |
Cytomap | 3p22.1 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A024R2Q1 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9117 | SEC22C | LZE4T | Human | Esophagus | ESCC | 1.33e-11 | 3.51e-01 | 0.0811 |
9117 | SEC22C | LZE7T | Human | Esophagus | ESCC | 5.52e-04 | 2.20e-01 | 0.0667 |
9117 | SEC22C | LZE8T | Human | Esophagus | ESCC | 2.21e-04 | 3.51e-02 | 0.067 |
9117 | SEC22C | LZE24T | Human | Esophagus | ESCC | 3.04e-05 | 1.68e-01 | 0.0596 |
9117 | SEC22C | LZE6T | Human | Esophagus | ESCC | 9.37e-06 | 1.38e-01 | 0.0845 |
9117 | SEC22C | P2T-E | Human | Esophagus | ESCC | 1.79e-11 | 1.73e-01 | 0.1177 |
9117 | SEC22C | P4T-E | Human | Esophagus | ESCC | 7.55e-23 | 4.57e-01 | 0.1323 |
9117 | SEC22C | P5T-E | Human | Esophagus | ESCC | 5.12e-15 | 1.69e-01 | 0.1327 |
9117 | SEC22C | P8T-E | Human | Esophagus | ESCC | 4.69e-13 | 1.36e-01 | 0.0889 |
9117 | SEC22C | P9T-E | Human | Esophagus | ESCC | 1.40e-09 | 1.68e-01 | 0.1131 |
9117 | SEC22C | P10T-E | Human | Esophagus | ESCC | 1.32e-15 | 2.63e-01 | 0.116 |
9117 | SEC22C | P11T-E | Human | Esophagus | ESCC | 6.20e-12 | 4.87e-01 | 0.1426 |
9117 | SEC22C | P12T-E | Human | Esophagus | ESCC | 4.31e-25 | 5.43e-01 | 0.1122 |
9117 | SEC22C | P15T-E | Human | Esophagus | ESCC | 1.60e-13 | 2.18e-01 | 0.1149 |
9117 | SEC22C | P16T-E | Human | Esophagus | ESCC | 4.18e-23 | 2.24e-01 | 0.1153 |
9117 | SEC22C | P17T-E | Human | Esophagus | ESCC | 4.78e-05 | 2.61e-01 | 0.1278 |
9117 | SEC22C | P19T-E | Human | Esophagus | ESCC | 3.43e-09 | 5.26e-01 | 0.1662 |
9117 | SEC22C | P20T-E | Human | Esophagus | ESCC | 5.23e-10 | 1.17e-01 | 0.1124 |
9117 | SEC22C | P21T-E | Human | Esophagus | ESCC | 1.49e-31 | 5.15e-01 | 0.1617 |
9117 | SEC22C | P22T-E | Human | Esophagus | ESCC | 1.08e-24 | 3.13e-01 | 0.1236 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
GO:000688815 | Esophagus | ESCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 102/8552 | 130/18723 | 1.73e-14 | 9.22e-13 | 102 |
GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
GO:000688821 | Liver | HCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 100/7958 | 130/18723 | 1.15e-15 | 8.67e-14 | 100 |
GO:004819315 | Oral cavity | OSCC | Golgi vesicle transport | 209/7305 | 296/18723 | 1.39e-28 | 6.30e-26 | 209 |
GO:00068888 | Oral cavity | OSCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 97/7305 | 130/18723 | 1.42e-16 | 1.15e-14 | 97 |
GO:004819314 | Prostate | Tumor | Golgi vesicle transport | 105/3246 | 296/18723 | 3.55e-14 | 4.33e-12 | 105 |
GO:000688813 | Prostate | Tumor | endoplasmic reticulum to Golgi vesicle-mediated transport | 49/3246 | 130/18723 | 2.49e-08 | 8.33e-07 | 49 |
GO:0048193110 | Skin | cSCC | Golgi vesicle transport | 153/4864 | 296/18723 | 1.85e-21 | 3.41e-19 | 153 |
GO:000688810 | Skin | cSCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 73/4864 | 130/18723 | 2.60e-13 | 1.57e-11 | 73 |
GO:004819320 | Thyroid | PTC | Golgi vesicle transport | 186/5968 | 296/18723 | 3.09e-28 | 1.22e-25 | 186 |
GO:000688817 | Thyroid | PTC | endoplasmic reticulum to Golgi vesicle-mediated transport | 83/5968 | 130/18723 | 6.19e-14 | 3.52e-12 | 83 |
GO:0048193111 | Thyroid | ATC | Golgi vesicle transport | 189/6293 | 296/18723 | 9.58e-27 | 5.05e-24 | 189 |
GO:000688823 | Thyroid | ATC | endoplasmic reticulum to Golgi vesicle-mediated transport | 84/6293 | 130/18723 | 4.40e-13 | 1.97e-11 | 84 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SEC22C | SNV | Missense_Mutation | novel | c.605N>T | p.Asn202Ile | p.N202I | Q9BRL7 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
SEC22C | SNV | Missense_Mutation | novel | c.41A>G | p.Asp14Gly | p.D14G | Q9BRL7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
SEC22C | SNV | Missense_Mutation | c.419N>C | p.Lys140Thr | p.K140T | Q9BRL7 | protein_coding | tolerated(0.23) | possibly_damaging(0.829) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SEC22C | SNV | Missense_Mutation | novel | c.729N>A | p.Phe243Leu | p.F243L | Q9BRL7 | protein_coding | deleterious(0.01) | benign(0.037) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SEC22C | SNV | Missense_Mutation | c.677N>T | p.Ala226Val | p.A226V | Q9BRL7 | protein_coding | tolerated(0.07) | probably_damaging(0.996) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SEC22C | SNV | Missense_Mutation | novel | c.638C>A | p.Ser213Tyr | p.S213Y | Q9BRL7 | protein_coding | deleterious(0.04) | probably_damaging(0.956) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SEC22C | SNV | Missense_Mutation | c.11N>G | p.Ile4Ser | p.I4S | Q9BRL7 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-K7-A5RF-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
SEC22C | SNV | Missense_Mutation | novel | c.77A>T | p.His26Leu | p.H26L | Q9BRL7 | protein_coding | tolerated(0.66) | benign(0.003) | TCGA-56-A62T-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | CR |
SEC22C | SNV | Missense_Mutation | c.806N>C | p.Leu269Pro | p.L269P | Q9BRL7 | protein_coding | deleterious(0.03) | benign(0.162) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SEC22C | SNV | Missense_Mutation | novel | c.328T>C | p.Tyr110His | p.Y110H | Q9BRL7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D7-A6EY-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |